Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Obermeier

Showing results (31-40 of 67) with videos related to

Pageof 7
Sort By:
Psychiatry Research|March 21, 2012
Impaired monocyte activation in schizophreniaNorbert Müller, Jenny K Wagner, Daniela Krause, et al.
JSES International|February 25, 2026
Grit is not associated with opioid consumption patterns in patients that undergo arthroscopic rotator cuff repairRebekah M Kleinsmith, Fernando A Huyke-Hernandez, Megan Reams, et al.
Pharmacopsychiatry|September 21, 2018
Comparing Schizophrenia Patients With a Predicted High/Low Risk of Nonresponse Receiving Treatment with Ziprasidone and Haloperidol: A Randomized-Controlled StudyRebecca Schennach, Michael Riedel, Ilja Spellmann, et al.
Orthopaedic Journal of Sports Medicine|April 8, 2020
Injury-Related Fears During the Return-to-Sport Phase of ACL Reconstruction RehabilitationAdam Meierbachtol, Michael Obermeier, William Yungtum, et al.
BMC Psychiatry|May 22, 2016
Stability of remission rates in a 3-year follow-up of naturalistic treated depressed inpatientsFlorian Seemüller, Michael Obermeier, Rebecca Schennach, et al.
Mental Illness|December 6, 2014
Infectious Agents are Associated with Psychiatric DiseasesDaniela Lydia Krause, Elif Weidinger, Judith Matz, et al.
Pharmacopsychiatry|February 27, 2020
Correction: Comparing Schizophrenia Patients With a Predicted High/Low Risk of Nonresponse Receiving Treatment with Ziprasidone and Haloperidol: A Randomized-Controlled StudyRebecca Schennach, Michael Riedel, Ilja Spellmann, et al.
BMC Medicine|July 4, 2012
Mirroring everyday clinical practice in clinical trial design: a new concept to improve the external validity of randomized double-blind placebo-controlled trials in the pharmacological treatment of major depressionEmanuel Severus, Florian Seemüller, Michael Berger, et al.
European Archives of Psychiatry and Clinical Neuroscience|January 25, 2012
Intracellular monocytic cytokine levels in schizophrenia show an alteration of IL-6Daniela L Krause, Jenny K Wagner, Agnes Wildenauer, et al.
Schizophrenia Research|June 24, 2010
Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatmentNorbert Müller, Daniela Krause, Sandra Dehning, et al.
Pageof 7

Showing results (31-40 of 67) with videos related to

Sort By:
Pageof 7
Psychiatry Research|March 21, 2012
Impaired monocyte activation in schizophreniaNorbert Müller, Jenny K Wagner, Daniela Krause, et al.
JSES International|February 25, 2026
Grit is not associated with opioid consumption patterns in patients that undergo arthroscopic rotator cuff repairRebekah M Kleinsmith, Fernando A Huyke-Hernandez, Megan Reams, et al.
Pharmacopsychiatry|September 21, 2018
Comparing Schizophrenia Patients With a Predicted High/Low Risk of Nonresponse Receiving Treatment with Ziprasidone and Haloperidol: A Randomized-Controlled StudyRebecca Schennach, Michael Riedel, Ilja Spellmann, et al.
Orthopaedic Journal of Sports Medicine|April 8, 2020
Injury-Related Fears During the Return-to-Sport Phase of ACL Reconstruction RehabilitationAdam Meierbachtol, Michael Obermeier, William Yungtum, et al.
BMC Psychiatry|May 22, 2016
Stability of remission rates in a 3-year follow-up of naturalistic treated depressed inpatientsFlorian Seemüller, Michael Obermeier, Rebecca Schennach, et al.
Mental Illness|December 6, 2014
Infectious Agents are Associated with Psychiatric DiseasesDaniela Lydia Krause, Elif Weidinger, Judith Matz, et al.
Pharmacopsychiatry|February 27, 2020
Correction: Comparing Schizophrenia Patients With a Predicted High/Low Risk of Nonresponse Receiving Treatment with Ziprasidone and Haloperidol: A Randomized-Controlled StudyRebecca Schennach, Michael Riedel, Ilja Spellmann, et al.
BMC Medicine|July 4, 2012
Mirroring everyday clinical practice in clinical trial design: a new concept to improve the external validity of randomized double-blind placebo-controlled trials in the pharmacological treatment of major depressionEmanuel Severus, Florian Seemüller, Michael Berger, et al.
European Archives of Psychiatry and Clinical Neuroscience|January 25, 2012
Intracellular monocytic cytokine levels in schizophrenia show an alteration of IL-6Daniela L Krause, Jenny K Wagner, Agnes Wildenauer, et al.
Schizophrenia Research|June 24, 2010
Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatmentNorbert Müller, Daniela Krause, Sandra Dehning, et al.
Pageof 7